Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1634 1683
This examiner grants 47% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18051488 | Association Of T Cell Leukemia/Lymphoma Protein 1A (TCL1A) With Clonal Hematopoiesis Of Indeterminate Potential (CHIP) | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17854283 | Methods Of Treating Asthma With Solute Carrier Family 27 Member 3 (SLC27A3) Inhibitors | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17854412 | Methods Of Treating A Metabolic Disorder With Mitogen-Activated Protein Kinase Kinase Kinase 15 (MAP3K15) Inhibitors | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17372113 | COMPOSITIONS AND METHODS RELATED TO DIFFERENTIALLY METHYLATED DNA SEQUENCES ASSOCIATED WITH MONOALLELIC GENE EXPRESSION AND DISEASE | Non-Final OA | North Carolina State University |
| 17776822 | METHODS OF SYNTHESIZING RNA MOLECULES | Non-Final OA | BAYER HEALTHCARE LLC |
| 18007097 | BIOMARKER FOR DIAGNOSING NONALCOHOLIC STEATOHEPATITIS USING MICRORNA COMBINATION | Final Rejection | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION |
| 18042167 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | Non-Final OA | OTSUKA PHARMACEUTICAL CO., LTD. |
| 17999137 | PERSONALISED RECOMMENDED DAILY INTAKE FOR NUTRIENTS BASED ON INDIVIDUAL GENETIC RISK SCORES | Final Rejection | SOCIETE DES PRODUITS NESTLE S.A. |
| 17794269 | AN EPIGENETIC CLOCK FOR GALLIFORMES | Final Rejection | EVONIK OPERATIONS GMBH |
| 17920652 | METHOD FOR DETECTING SEVERITY OF PREMENSTRUAL SYNDROME | Non-Final OA | KAO CORPORATION |
| 18010878 | CLEAVAGE-AMPLIFICATION BIOSENSOR AND METHODS OF USE THEREOF | Non-Final OA | McMaster University |
| 18168955 | METHODS OF DETERMINING COVID-19 MORTALITY RISK | Non-Final OA | WASHINGTON UNIVERSITY |
| 17831103 | SYSTEMS AND METHODS FOR MULTIMODAL ANALYSIS OF SURGICAL DRAIN FLUID USING INTERCHANGEABLE AND CUSTOMIZABLE NUCLEIC ACID BASED TESTS | Final Rejection | Washington University |
| 17926804 | EPIGENETIC MODIFICATION OF SELECT GENES AS MARKERS OF HYPERSOMNOLENCE | Non-Final OA | Wisconsin Alumni Research Foundation |
| 18340581 | COMPOSITIONS AND METHODS FOR HIGHLY SENSITIVE DETECTION OF TARGET SEQUENCES IN MULTIPLEX REACTIONS | Non-Final OA | Life Technologies Corporation |
| 17811995 | LNCRNAS FOR THERAPY AND DIAGNOSIS OF CARDIAC HYPERTROPHY | Final Rejection | Medizinische Hochschule Hannover |
| 17796293 | Biomarkers for Risk Prediction of Parkinson's Disease | Final Rejection | SINGAPORE HEALTH SERVICES PTE LTD |
| 17788476 | Disease Detection in Liquid Biopsies | Final Rejection | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D |
| 18258485 | IDENTIFICATION AND TREATMENT OF PATIENTS WITH EPILEPSY | Non-Final OA | Jazz Pharmaceuticals Research UK Limited |
| 18593639 | NON-INVASIVE PRENATAL TESTING AT EARLY STAGE OF PREGNANCY | Final Rejection | BillionToOne, Inc. |
| 18245957 | APPARATUS, KITS AND METHODS FOR PREDICTING THE DEVELOPMENT OF SEPSIS | Non-Final OA | The Secretary of State for Defence |
| 17846157 | DIAGNOSIS OF FRONTOTEMPORAL DEMENTIA | Final Rejection | UCL Business Ltd |
| 17787433 | NOVEL DRUGGABLE TARGETS FOR THE TREATMENT OF INFLAMMATORY DISEASES SUCH AS SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND METHODS FOR DIAGNOSIS AND TREATMENT USING THE SAME | Final Rejection | THE CHILDREN'S HOSPITAL OF PHILADELPHIA |
| 17905021 | METHODS AND KITS FOR TREATING OR DIAGNOSING CANNABINOID HYPEREMESIS SYNDROME | Non-Final OA | CReDO Science, LLC |
| 18009625 | METHOD OF DIAGNOSING MITOCHONDRIAL DNA DISORDERS USING STOOL SAMPLES | Non-Final OA | University of Newcastle Upon Tyne |
| 17926306 | DETECTION AND TREATMENT OF CONDITIONS CHARACTERIZED BY PERFUSION SHORTAGE | Non-Final OA | Falcon BioScience, LLC |
| 17898757 | STIMULATION OF THE HEALING PROCESS ON THE RETINAL PIGMENT EPITHELIUM AFTER R:GEN WITH RTF TECHNOLOGY | Non-Final OA | Lutronic Vision, Inc. |
| 17801979 | METHOD FOR SELECTING NORMALIZING GENES FOR COPY NUMBER VARIATION DETECTION AND COMPOSITION FOR DETECTING C-MET COPY NUMBER VARIATION SELECTED BY METHOD | Non-Final OA | ABION INC. |
| 17874258 | Method of Diagnosis of Chronic Kidney Disease with Pharmacogenomics Support | Final Rejection | Machaon Diagnostics, Inc. |
| 17782314 | A BIOMARKER AND USES THEREFOR | Non-Final OA | Perron Institute for Neurological and Translational Science Limited |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy